PRESS RELEASE: Medigene and Difa Cooper enter into agreement for the commercialization of Veregen(R) in Italy

MediGene AG / Medigene and Difa Cooper enter into agreement for the commercialization of Veregen(R) in Italy . Ad hoc announcement according to -- 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Martinsried/Munich, 06 August, 2013. Medigene AG http://www.medigene.de/ (MDG, Frankfurt, Prime Standard) announces the conclusion of an exclusive license and supply agreement with Difa Cooper SPA, the Italian subsidiary of the Spanish pharmaceutical company IFC (Industrial Farmaceutica Cantabria), for the supply and commercialization of Veregen(R) in Italy. After approval Difa Cooper will promote and distribute the drug for the treatment of genital warts. In addition to a one-time upfront payment, Medigene will also obtain revenues from milestone payments, from the supply of the finished product, as well as double-digit royalties on the future sales of Veregen(R) .

Dr. Frank Mathias, Chief Executive Officer of Medigene AG, comments: "We are glad that we will now be able to open up the Italian market with this marketing partnership. Difa Cooper is a renowned Italian pharmaceutical company with a focus on dermatology, and will approach all relevant target groups with the drug. We have established sales networks for Veregen(R) in almost all European countries, and the drug is currently available on prescription in six European countries."

Dr. Stefano Fatelli, General Manager of Difa Cooper, of Difa Cooper, adds: "This innovative ointment for the topical treatment of genital warts complements our product portfolio and strengthens our competitive position. We look forward to driving forward the approval and commercialization of Veregen(R) in Italy."

Veregen(R) is already being marketed in the USA (by Fougera), in Germany, Austria and Switzerland (by Abbott), in Spain (by Bial), in Serbia (by Pharmanova) as well as in the Netherlands (by Will-Pharma) and approved in further countries. Market approvals and the launch of Veregen(R) in several other countries are pending in 2013. The marketing authorization application for Italy and the remaining European countries is in preparation. Medigene has entered into several marketing partnerships for Veregen(R) across Europe, Asia, and America, and is planning to continue this global licensing strategy to further leverage the product's market potential.

About Veregen(R) : Veregen(R) , a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. In its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% ointment (Veregen(R) ) as a possible option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment (Veregen(R) ) has been included in the current European guideline on the treatment of genital warts, the 2012 European Guideline for the Management of Anogenital Warts.

Difa Cooper: Difa Cooper is a pharmaceutical company specializing in dermatology and has been operating in the Italian pharmacies market for more than 50 years. It is part of the IFC Group (Industrial Farmaceutica Cantabria) based in Madrid. IFC develops, manufactures, and distributes dermatological products, pharmaceuticals, cosmetics, nutritional supplements, and technologies. The IFC sales network covers more than 50 countries worldwide. For more information, please visit http://www.difacooper.com.

Medigene AG (Frankfurt: MDG, Prime Standard) is a publicly listed biotech company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to generate revenues from a marketed product (Veregen(R) ), which is distributed by partner companies. Medigene also has two drug candidates undergoing clinical trials, EndoTAG(R) -1 und RhuDex(R) , and is developing an innovative vaccine technology. For further details, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene(R) and Veregen(R) are registered trademarks of Medigene AG. Polyphenon E(R) is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.

Contact

Julia Hofmann, Claudia Burmester

Investor & Public Relations

Tel.: +49 - 89 - 20 00 33 - 33 01

Email: investor@medigene.com

To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.

Press release as PDF: http://hugin.info/132073/R/1721187/573184.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Medigene AG via Thomson Reuters ONE

HUG#1721187

--- End of Message ---

Medigene AG

Lochhamer Strasse 11 Martinsried / München Germany

WKN: 502090;ISIN: DE0005020903;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.medigene.com (END) Dow Jones Newswires

   August 06, 2013 01:31 ET (05:31 GMT)- - 01 31 AM EDT 08-06-13